(84) Studies examining AT1R expression in human ovarian cancer and attempting to determine whether AT1R blockers could inhibit tumor progression showed AT1R expression in 85% invasive ovarian adenocarcinomas, 66% borderline malignancies, and 14% benign cystadenomas. Here, AGTR1 is linked to cystadenoma.